Yamaha Motor Establishes Second Fund for Corporate Venturing
– Exploring technologies and opportunities aimed at new business domain expansion and securing competitive advantages…
Year: 2023
Evolving Usage Models and Tightened Budgets Further Hinder Adoption of Thin Clients, According to IDC
NEEDHAM, Mass.–(BUSINESS WIRE)–#EnterpriseClientDevices–Faced with an ongoing transition towards alternative devices and challenged budgets, global shipments…
Hedgehog Lab: Boston Tech Consultancy Eyes United States Growth with Key C-Suite Hire
BOSTON–(BUSINESS WIRE)–Hedgehog Lab, a global tech consultancy with a human-centered approach, has named Edward Marshall…
Infogain Announces the Appointment of Neha Kathuria as Chief Marketing Officer
Strengthening the executive leadership team to support the company’s future growth plans LOS GATOS, Calif.–(BUSINESS…
Everything You Need to Know About Creating a Knowledge Base
When you mention a knowledge base, many people envision a collection of thin articles, hard…
Starfleet Innotech and PPM Toys Execute an MOU Agreement for Starfleet to Acquire a Majority Ownership Interest in PPM Toys
New York, New York–(Newsfile Corp. – March 13, 2023) – Starfleet Innotech, Inc. (OTC Pink:…
American Aires Announces Revocation of Failure-to-File Cease Trade Order
Toronto, Ontario–(Newsfile Corp. – March 13, 2023) – American Aires Inc. (CSE: WIFI) (OTC Pink:…
U.S. District Court Grants Summary Judgment, Win for Physicians Against Nationwide Equipment Finance Lender Balboa Capital
Cites practice of not providing invoice including principal in loan documents sent to borrowers DALLAS–(BUSINESS…
ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:…
ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:…
Shiru launches OleoPro™, a protein-based alternative fat ingredient to unlock the next generation of plant-based foods
Shiru’s first commercial product, OleoPro™, delivers a 90% saturated fat reduction and improved taste performance…
Shiru launches OleoPro™, a protein-based alternative fat ingredient to unlock the next generation of plant-based foods
Shiru’s first commercial product, OleoPro™, delivers a 90% saturated fat reduction and improved taste performance…
Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) — (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company)…
Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) — (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company)…
Intelligent Bio Solutions Inc. Selects HASTA Laboratory as Drug Testing Specialist in Australia
NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions”…
Intelligent Bio Solutions Inc. Selects HASTA Laboratory as Drug Testing Specialist in Australia
NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions”…
Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage…
Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage…
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue…
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue…